Search clinical trials for: GI-6301 Vaccine (Yeast- Brachyury)

Total 48 results

National Cancer Institute (NCI)

Completed

Cancer Vaccine Targeting Brachyury Protein in Tumors

Neoplasms | Adenocarcinoma | Colon Neoplasms | Malignant Solid Tumors

United States
NantCell, Inc.
National Cancer Institute (NCI)

Completed

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

Chordoma

United States
National Cancer Institute (NCI)

Completed

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Lung Cancer | Prostate Cancer

United States
University of Pennsylvania

Withdrawn

GI-4000 With Adoptive Transfer in Pancreatic Cancer

Pancreatic Cancer
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Solid Tumor | Prostate Cancer | Advanced Solid Tumor | Metastatic Prostate Cancer | Prostate Neoplasm

United States
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Completed

A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine

Norwalk Gastroenteritis | Norovirus Infections

China
National Cancer Institute (NCI)

Completed

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Prostatic Neoplasms | Prostatic Cancer

United States
National Vaccine and Serum Institute, China
Zhengzhou University; Lanzhou Institute of Biological Products Co., Ltd; Beijing...

Recruiting

Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

Norwalk Gastroenteritis | Norovirus Infections

China
National Cancer Institute (NCI)

Completed

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Neoplasms | Breast Cancer | Lung Cancer | Prostate Cancer | Colon Cancer

United States
SENAI CIMATEC

Recruiting

Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

SARS-CoV-2

Brazil
Icon Genetics GmbH
University Hospital, Ghent

Completed

Recombinant, Bivalent, Norovirus Vaccine Study

Norovirus

Belgium
Vaxart

Active, not recruiting

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Norovirus Infections

United States
Vaxart

Completed

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers ((VXA-G1-1-NN))

Norovirus Infections

United States
National Cancer Institute (NCI)

Recruiting

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Lynch Syndrome

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

United States
Takeda

Completed

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Norovirus

United States
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
Takeda

Completed

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Healthy Participants | Norovirus

United States
Takeda

Completed

Bivalent Norovirus Vaccine Study

Gastroenteritis

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Clinical Study of MT-2301

Haemophilus Influenza Type b

Japan
Takeda

Completed

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

Healthy Volunteers

United States
Laboratoires Mayoly Spindler

Completed

Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome
Wu Jiang
Beijing Municipal Science & Technology Commission

Completed

Dose of Hepatitis B Vaccines in Non/Low-response Populations

Vaccination; Complications, Reaction, Serum

China
Zahra Sohrabi
Shiraz University of Medical Sciences

Completed

Effect of Selenium Supplementation on Inflammatory,Oxidative and Nutritional Markers in Hemodialysis Patients

Inflammation | Malnutrition | Complication of Hemodialysis

Iran, Islamic Republic of
ImmunityBio, Inc.

Withdrawn

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Colorectal Cancer Metastatic | mCRC

United States
University Hospital Inselspital, Berne

Recruiting

Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab. (RituxiVac)

Immunosuppression | Rituximab | COVID19 Vaccination

Switzerland
Folia Biotech Inc.

Unknown

Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults

Flu

Canada
ImmunityBio, Inc.

Withdrawn

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Hepatocellular Carcinoma Non-resectable | Hepatocellular Carcinoma Recurrent

United States
ImmunityBio, Inc.

Unknown

QUILT-3.080: NANT Pancreatic Cancer Vaccine

Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Chordoma | Unresectable Malignant Neoplasm

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Triple Negative Breast Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)

Triple Negative Breast Cancer (TNBC)

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Triple Negative Breast Cancer
ImmunityBio, Inc.

Unknown

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Squamous Cell Carcinoma

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Metastatic Pancreatic Cancer

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Head and Neck Squamous Cell Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Non-small Cell Lung Cancer
Boehringer Ingelheim

Completed

Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.

Sleep Initiation and Maintenance Disorders

China
ImmunityBio, Inc.

Withdrawn

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Urothelial Carcinoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Colorectal Cancer
Nanfang Hospital, Southern Medical University

Recruiting

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

End Stage Liver Disease | Portal Hypertension | Jaundice | Liver Dysfunction

China
ImmunityBio, Inc.

Withdrawn

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma
ImmunityBio, Inc.

Withdrawn

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Ovarian Cancer
Cumberland Pharmaceuticals

Terminated

Safety and Efficacy Study of a New Formulation of Acetylcysteine Injection

Acetaminophen Overdose

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Merkel Cell Carcinoma
Myovant Sciences GmbH

Completed

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Spain, Hungary, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Poland, Portugal, South Africa, Ukraine
Myovant Sciences GmbH

Completed

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Endometriosis Related Pain

United States, Poland, Australia, Brazil, Chile, Czechia, Georgia, Italy, New Zealand, Romania, Sweden

3

Subscribe